Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole effect on AZD9291 pharmacokinetics in EGFR-mutant NSCLC
NCT02157883Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration of AZD9291 at Day 10 and Area Under the Plasma Concentration-Time Curve of AZD9291 at Day 10. Started Nov 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02157883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157883.